⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 31, 2011HaematologicaOpen Access

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)

Giuseppe Visani Massimo Breccia Enrico Montefusco Enrica Morra Valeria Santini Alessandro Isidori

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The Incidence of Pleural and Pericardial Effusion Is Not Higher in Patients Receiving Dasatinib at Low Doses.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Visani et al. (2011) studied this question.

synapsesocial.com/papers/6a96ed88f34ac7d5e5823d26 https://doi.org/10.3324/haematol.2011.041319

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1The importance of preparation for or achieving accreditation for small and high volume hematopoietic cell transplantation programsHaematologica · 2026
2BCL6 in B-cell lymphomas: old target, new tricks?Haematologica · 2026
3Platelet transfusion biology: from hemostatic support to inflammatory and immune signalingHaematologica · 2026
4Quizartinib in older patients (aged ≥60 years) with newly diagnosed FLT3-ITDpositive acute myeloid leukemia: subgroup analyses from QuANTUM-FirstHaematologica · 2026
5Clinical risk features and genetic findings in essential thrombocythemia and polycythemia vera of childhood and adolescence: prospective insights from the German MPN Childhood RegistryHaematologica · 2026
6Venetoclax plus azacitidine in younger adults with acute myeloid leukemia beyond historical comparisons. Comment on: "Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy"Haematologica · 2026
7Effects of secondary factor VIII prophylaxis on joint and bone health in a hemophilia A mouse modelHaematologica · 2026
8Response to Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”Haematologica · 2026
9Hyperinflammatory differentiation syndrome with hemophagocytic lymphohistiocytosis-like features following menin inhibition in acute myeloid leukemiaHaematologica · 2026
10Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expressionHaematologica · 2026

More from Haematologica